Senti Biosciences, Inc. 8-K

What Happened

• Senti Biosciences (SNTI) filed an 8-K reporting a First Amendment to Lease and related agreements, effective September 1, 2025, that reduce its leased Alameda, CA premises from about 91,910 rentable sq ft to about 45,955 rentable sq ft. The company also amended its sublease with GeneFab, and the landlord agreed to the changes in exchange for a $1.0 million “Reduction Fee.”

Key Details

• Space cut: from ~91,910 to ~45,955 rentable sq ft (effective Sept 1, 2025).
• New base rent for remaining space: $188,311/month (Sept 1, 2025–July 31, 2026), rising in scheduled steps to $293,010/month (Aug 1–Aug 31, 2032); intermediate amounts are specified in the filing.
• Operating expense/tax share reduced to 50% as of the Effective Date; Senti remains responsible for 100% of building utilities until surrendered space is re-let.
• Landlord may draw $2.0 million from Senti’s existing $2.76 million letter of credit (LOC); required LOC balance thereafter will be $760,000.
• Sublease changes: GeneFab’s amended sublease aligns its rent/expense obligations with Senti’s and includes responsibility for the $1.0 million Reduction Fee per the landlord consent. GeneFab owed Senti $1,374,005 in outstanding base rent, which may be satisfied in whole/part by a prepayment credit for work/services and must be paid in full by Sept 1, 2026 if unpaid.

Why It Matters

• The amendments materially reduce Senti’s occupied footprint and near-term base rent obligations for the smaller space, but they also trigger cash impacts: a $2.0M draw on the company’s LOC (reducing available credit) and a $1.0M reduction fee payable to the landlord (by Senti or GeneFab).
• The sublease/letter agreement shifts some economic risk to GeneFab but includes a credit arrangement and default provisions; if GeneFab does not satisfy its obligations, Senti could face immediate default consequences and potential cash exposure.
• Investors should view these as balance-sheet and liquidity items: they change future rent expense and contingent cash flows, and they affect the company’s available LOC and near-term cash position.